Tirzepatide vs Semaglutide: Where the Newer Drug Wins and Where It Doesn't
In the only randomized trial that put tirzepatide directly against semaglutide for weight loss, people on tirzepatide lost an average of 20.2% of their starting weight. People on semaglutide lost 13.7%. The 6.5-percentage-point gap held across nearly every secondary outcome the trial measured.
That difference matters because the choice between these two drugs is rarely about whether they work. Both work. The question is how much extra benefit tirzepatide buys, what it costs in side effects, and whether semaglutide's longer track record on heart outcomes outweighs the smaller weight number.
The Head-to-Head Trial
SURMOUNT-5 was a 72-week phase 3b open-label study of 751 adults with obesity but without type 2 diabetes. Participants were randomized 1:1 to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg), injected once weekly.
By week 72:
- Mean weight change was −20.2% with tirzepatide vs −13.7% with semaglutide.
- Waist circumference dropped by 18.4 cm vs 13.0 cm.
- Both differences were statistically significant at P<0.001.
More tirzepatide participants also hit each weight-reduction threshold the trial measured (≥10%, ≥15%, ≥20%, ≥25%). A separate post-hoc analysis tracking time-to-threshold found tirzepatide users reached each milestone earlier and stayed there longer. Another analysis modeled 10-year cardiovascular risk using the same SURMOUNT-5 cohort and found a larger absolute reduction with tirzepatide (−2.4% vs −1.4%).
At a Glance
| Outcome | Tirzepatide | Semaglutide | Difference | Evidence |
|---|---|---|---|---|
| Weight loss in obesity, no diabetes (72w) | −20.2% | −13.7% | 6.5 pts | Strong (RCT, head-to-head) |
| Weight loss in T2D (40w, SURPASS-2) | greater at all 3 doses | reference | 1.9 to 5.5 kg more | Strong (RCT, head-to-head) |
| Real-world weight loss at 12 months | ≥5%, ≥10%, ≥15% more often | reference | HR 1.76 to 3.24 | Moderate (cohort, n=18,386 matched) |
| Cardiovascular outcomes data | Trials ongoing (HFpEF, T2D) | MACE reduced 20% in 17,604-patient trial | Semaglutide has more endpoint data | Strong for semaglutide; emerging for tirzepatide |
| Common side effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea | Mostly similar; vomiting slightly more frequent on tirzepatide | Strong |
In Type 2 Diabetes
SURPASS-2 was the first head-to-head trial between the two drugs, run in adults with type 2 diabetes for 40 weeks. All three tirzepatide doses (5, 10, 15 mg) beat semaglutide 1 mg on glycemic control and weight loss. The between-group weight differences were 1.9 to 5.5 kg in tirzepatide's favor, and the trial's primary endpoint (HbA1c reduction) crossed both noninferiority and superiority thresholds.
A caveat: SURPASS-2 used semaglutide 1 mg, the dose approved for diabetes. The maximum semaglutide dose for weight loss is 2.4 mg, and that higher dose was not tested in SURPASS-2. SURMOUNT-5, which did use semaglutide at its weight-loss dose, still showed tirzepatide ahead.
For people with both obesity and type 2 diabetes, SURMOUNT-2 tested tirzepatide against placebo for 72 weeks. Tirzepatide produced 12.8% to 14.7% weight loss depending on dose, while placebo produced 3.2%. About 80% of tirzepatide users lost at least 5% of their body weight.
Real-World Data
A 2024 cohort study followed 18,386 propensity-matched patients on tirzepatide or semaglutide labeled for type 2 diabetes. Tirzepatide users were more likely to hit each weight-loss threshold within a year, with hazard ratios of 1.76 for ≥5% loss, 2.54 for ≥10%, and 3.24 for ≥15%.
Average weight loss was about 7 percentage points greater on tirzepatide at 12 months, and gastrointestinal side effects occurred at similar rates in both groups.
The cohort includes a mix of intermittent users, dose escalators, and people who stopped early, which is why real-world numbers are smaller than trial results. The pattern of advantage is consistent.
Where Semaglutide Leads
Tirzepatide wins on weight, but semaglutide has more cardiovascular outcome data in obesity. The SELECT trial randomized 17,604 adults with cardiovascular disease and overweight or obesity (no diabetes) to semaglutide or placebo. After roughly 40 months, semaglutide reduced major adverse cardiovascular events by about 20%.
Tirzepatide doesn't yet have an analogous trial in obesity without diabetes. SURPASS-CVOT, comparing tirzepatide against dulaglutide in type 2 diabetes patients with cardiovascular disease, is fully recruited and ongoing. A separate trial showed tirzepatide reduced cardiovascular death or worsening heart failure in patients with HFpEF and obesity, suggesting cardiovascular benefit beyond weight loss alone.
A 2021 meta-analysis of GLP-1 receptor agonists pooled 8 trials and confirmed the class as a whole reduces MACE, all-cause mortality, hospitalizations for heart failure, and worsening kidney function in type 2 diabetes. Semaglutide and tirzepatide are both in that class.
Side Effects and Tolerability
Both drugs cause the same family of side effects, mostly gastrointestinal. Nausea, vomiting, diarrhea, and constipation are common, usually mild to moderate, and concentrated during dose escalation.
In SURMOUNT-5, gastrointestinal events were more frequent on tirzepatide for vomiting specifically. Discontinuation rates for adverse events were similar but slightly higher with tirzepatide at the maximum dose. A 2024 network meta-analysis of 76 trials found higher-dose GLP-1 drugs carried more gastrointestinal events than lower doses, with the trade-off being faster glycemic and weight benefit.
Hypoglycemia is rare for either drug when used alone; it becomes a concern in combination with insulin or sulfonylureas. Pancreatitis, gallbladder disease, and thyroid C-cell tumors are listed warnings for both classes; the absolute event rates have stayed low across the major trials.
Why Tirzepatide Tends to Win
Tirzepatide activates two receptors: GLP-1 (the same target as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). Adding GIP appears to expand the brain's appetite signaling beyond what GLP-1 covers alone, and may improve insulin sensitivity and lipid handling in adipose tissue. Some research also suggests dual agonism is better tolerated at the same level of GLP-1 engagement, which lets patients reach higher effective doses.
The mechanistic story is still being worked out. Whether GIP needs to be agonized or antagonized for the metabolic benefit remains debated, and triple agonists targeting GLP-1, GIP, and glucagon are now in late-stage trials with even larger weight-loss numbers in early data.
Picking Between Them
The data point in one direction for weight loss and a different direction for established cardiovascular outcomes:
- For weight loss alone, tirzepatide has the edge in every head-to-head and indirect comparison published so far.
- For cardiovascular risk reduction in obesity without diabetes, semaglutide has the only completed outcome trial.
- For type 2 diabetes, both drugs are CV-protective; tirzepatide brings additional weight loss and slightly better glycemic control on average.
- For tolerability, the patterns are similar, with vomiting more common on tirzepatide at top doses.
If the goal is the most weight loss possible, tirzepatide is the stronger statistical bet. If you have established cardiovascular disease without diabetes, semaglutide currently has the better-documented outcome data. Either drug requires a clinician to titrate the dose, monitor for side effects, and adjust if symptoms become intolerable.
Instalab's GLP-1 Program ($99) pairs you with a licensed physician who prescribes whichever drug fits your situation, runs the labs that justify staying on it, and adjusts the dose over time as your tolerance and response evolve.
What This Means If You're Choosing a GLP-1
The 6.5-point gap from SURMOUNT-5 is real, and it shows up in every population that's been compared. But it's a population average, and individual response varies widely.
People at the median lost about a fifth of their body weight on tirzepatide and an eighth on semaglutide. Some people on either drug lost much more or much less.
The right drug for one person isn't the same as the right drug for another. The trial data tells you the odds. A clinical conversation that factors in your starting weight, your other health conditions, your insurance, and your tolerance for side effects tells you the rest.
Prescribed by a licensed physician. Sent to your pharmacy.